TESAMORELIN
$80.00
Tesamorelin is a growth hormone-releasing hormone analogue which is researched for its ability to decrease visceral adipose tissue..
Description
Tesamorelin 10mg
 |
|
| Clinical data | |
|---|---|
| Trade names | Egrifta SV |
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a611035 |
| Routes of administration |
Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ≤4%[1] |
| Metabolism | Proteolysis |
| Elimination half-life | 26–38 min |
| Excretion | Renal/proteolysis |
| Identifiers | |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C221H366N72O67S |
| Molar mass | 5135.86 g·mol−1 |
| 3D model (JSmol) | |
Additional information
| Weight | 10mg, 5 vial kit 10mg, 40mg |
|---|
